We performed a randomized trial to determine whether there are differential effects of G-CSF when it is either started on the day (day 0 group) or on the 6th day of marrow infusion (day 5 group) in the allogeneic BMT setting. G-CSF 450 g was given intravenously daily until the peripheral blood ANC was over 3000/l. Between May 1995 and April 1998, 60 patients were enrolled (30 in each group). Median number of days of G-CSF administration was significantly longer for the day 0 group (18.5 vs 14.0 days, P Ͻ 0.001). Median days to an ANC over 500/l were the same in both groups (16 days). Median days to an unsupported platelet count of 20 000/l did not show significant differences (29.5 vs 28 days, P = 0.202). The frequency of hepatic VOD was higher for the day 0 group (66.7 vs 40.0%, P = 0.038). Mean plasma antithrombin III level was significantly lower in the day 0 group on post-transplant day 7 (83.6 vs 93.9%, P = 0.009). Patients in the day 0 group showed significantly worse 100-day survival (25/30 vs 30/30 surviving respectively, P = 0.019). In conclusion, early initiation of G-CSF after allogeneic BMT did not facilitate marrow engraftment. In addition, early administration of G-CSF was associated with a higher frequency of VOD and a significant fall in plasma antithrombin III level.
G-CSF is a glycoprotein hormone that regulates the proliferation and differentiation of hematopoietic progenitor cells.
1,2 G-CSF increases the peripheral blood neutrophil count by stimulating proliferation and shortening the bone marrow transit time. 3 In addition, G-CSF regulates the function of mature granulocytes with enhancement of phagocytosis, increased chemotaxis, increased cytotoxicity in vitro and modulation of cytokine release. [4] [5] [6] [7] Use of hematopoietic colony-stimulating factors has been shown to accelerate the rate of neutrophil engraftment after autologous and allogeneic BMT. [8] [9] [10] [11] [12] [13] [14] Some of the trials also reported decreased duration of fever and antibiotic use. Currently, hematopoietic colony-stimulating factors such as G-CSF and GM-CSF are used widely after autologous or allogeneic BMT. 13 However, the optimum timing of the initiation of hematopoietic colony-stimulating factor after the infusion of hematopoietic progenitor cells remains to be defined.
Therefore, we initiated a randomized trial to determine whether there are differential effects of G-CSF when it is either started on the day of bone marrow infusion (day 0 group) or started on the 6th day after marrow infusion (day 5 group) in a setting of allogeneic BMT.
Patients and methods

G-CSF administration
All patients gave written informed consent. The random assignment of G-CSF treatment was done at the start of the preparative regimen with stratification per disease category (malignant disorders including myelodysplastic syndrome vs severe aplastic anemia) and disease status (standard risk vs high risk) in cases of leukemias. Myelodysplastic syndrome was considered to be a standard risk. Those patients assigned to the day 0 G-CSF group received G-CSF (Amgen, Thousand Oaks, CA, USA) 450 g mixed in 100 ml of dextrose water intravenously over 3 h daily starting on the day of bone marrow infusion. Those patients assigned to day 5 group received the same dose of G-CSF daily starting on the 6th day (day 5) after bone marrow infusion. In both groups, the administration of G-CSF was continued until the peripheral blood ANC was over 3000/l.
Preparative regimens
All patients with malignant disorders including myelodysplastic syndrome received the BuCy regimen (busulfan 4 mg/kg/day on day −7 to day −4 and cyclophosphamide 60 mg/kg/day on day −3 to day −2). All patients with severe aplastic anemia received the Cy-ATG regimen (cyclophosphamide 50 mg/kg/day on days −5 to −2 and antithymocyte globulin 30 mg/kg/day on days −4 to −2).
Graft-versus-host disease prophylaxis
The regimens for the prophylaxis of GVHD included cyclosporine 1.5 mg/kg intravenously every 12 h starting on day 592 −1, then switched to an oral dose of four times the intravenous dose when oral intake became feasible. Methotrexate 15 mg/m 2 was given intravenously on day 1, then 10 mg/m 2 was given on days 3, 6 and 11. Methotrexate was not given if there was grade III or a higher degree of oral mucositis. If there was no evidence of GVHD, the cyclosporine dose was tapered by 10% each month starting on day 60.
Hepatic veno-occlusive disease (VOD) prophylaxis
Heparin was administered to those patients who received the BuCy regimen at a dose of 100 units/kg/day from day −7 to day 30. Heparin was discontinued if there was clinically significant bleeding or the partial thromboplastin time exceeded 1.2 times the upper limit of control.
Supportive care
Supportive care included diphenylhydantoin during busulfan administration and intravenous hydration, as well as mesna during cyclophosphamide administration. Ciprofloxacin 500 mg was given orally twice a day until the ANC was over 3000/l. Intravenous globulin 500 mg/kg was given once every 2 weeks from day −7 until day 120, then monthly until day 180.
Monitoring of the patients
Blood was drawn every day for complete blood count and reticulocyte count. Blood chemistry and electrolytes including magnesium level were done twice weekly or more frequently as necessary. A blood coagulation screen was done once a week or more frequently as necessary. All patients were monitored prospectively for the occurrence of adverse events, including GVHD, VOD and infections. Acute and chronic GVHDs were classified according to the criteria of Thomas et al 15 and Sullivan et al, 16 respectively. A diagnosis of VOD was made according to the clinical criteria of McDonald et al 17 as having two of the following before day 20 of BMT: (1) hyperbilirubinemia (bilirubin у2.0 mg/dl or 34.2 mol/l), (2) painful hepatomegaly, and (3) unexplained weight gain (Ͼ2% from baseline), no other explanation for these signs and symptoms being present at the time of diagnosis. The severity of VOD was classified into mild, moderate, or severe. 18 In brief, patients who met the criteria of VOD, but who were not treated and whose illness was self-limited, were considered to have mild VOD. Those whose VOD resolved but who received treatment such as diuretics for fluid retention or narcotic analgesics for painful hepatomegaly, were considered to have moderate VOD. Patients who died of VOD or whose VOD did not resolve by day 100 of BMT were considered to have severe VOD. The onset of VOD was defined as the day on which total serum bilirubin exceeded 2.0 mg/dl or body weight increased more than 2% above baseline. Transfusion requirements within 60 days of BMT were recorded.
Criteria for bone marrow engraftment
The first days of ANC equal or over 500/l and 1000/l for 2 consecutive days were recorded for neutrophil engraftment. The first day of unsupported platelet count equal or over 20 000/l for 7 consecutive days was recorded. For platelet counts of 50 000 and 100 000/l, the first day of two consecutive tests was recorded. When the patients were independent of red blood cell (RBC) transfusion for over a month, the last day of RBC transfusion was recorded as a day of RBC transfusion independence. The first day of the reticulocyte count equal or over 1% for 3 consecutive days was recorded.
Assays of hemostatic parameters
Monitoring of changes in protein C, free protein S, antithrombin III (ATIII), von Willebrand factor (vWF), and factor VIII was initiated in consecutive allogeneic BMT patients as a part of an ongoing prospective study when the seventh patient was enrolled into the current study. 19 Each hemostatic parameter was determined before preparative chemotherapy, on the day of marrow infusion (day 0), and on days 7, 14 and 21. Protein C was measured by a commercially available enzyme-linked immunosorbent assay (ELISA) using monoclonal antibodies (Asserachrom-Protein C; Stago, Asnières, France). Free protein S and wWF antigen were also determined by a commercially available ELISA using monoclonal antibodies (Asserachrom-Free Protein S, Asserachrom-vWF; Stago). ATIII was measured by chromogenic assay (Stachrome-AT III; Stago). Factor VIII was measured using Stago-Deficient VIII (Stago).
Statistical analysis
Categorical variables were compared using the chi-square test. Continuous variables were compared using Student ttest with or without log conversion as appropriate. Time to engraftment and survival curves were plotted by KaplanMeier method and compared using log-rank test.
Results
Patient characteristics
Between May 1995 and April 1998, 60 patients were enrolled (30 in the day 0 group and 30 in the day 5 group). The characteristics of the patients are listed in Table 1 . There were no significant differences between the two groups of patients with respect to various clinical characteristics. The median age of the patients was 33.5 years (range, 17-49) for the day 0 group and 31.5 years (range, for the day 5 group. Sixteen patients in each group were male. Twenty-three patients in the day 0 group and 21 patients in the day 5 group had standard-risk malignant disorders. There were five and six patients with severe aplastic anemia in each group, respectively. The majority of patients had Karnofsky performance status of 90-100% and received marrow from HLA fully matched siblings. Bone marrow cell doses given to each group of patients were 593 /kg (range, 0.27-3.10) to day 5 group. Most of the patients had their day 11 methotrexate dose for GVHD prophylaxis omitted due to grade III oral mucositis. There was no significant difference between the two groups of patients in terms of history of liver disease, liver function test results, history of infection, and hepatitis B serology status prior to BMT.
Duration of G-CSF administration
The median number of days of G-CSF administration in the day 0 group was 18.5 (range 15-36) which is significantly longer when compared to the day 5 group (median 14 days, range 8-28, P Ͻ 0.001, Table 2 ).
Engraftment
All patients in the study achieved ANC over 1000/l for at least 2 consecutive days. Median days to ANC over 500/l and 1000/l were the same in both group (16 and 17 days, respectively) (Table 2, Figure 1a ). Figure 2a shows that the ANC on day 3 of BMT is significantly higher in the day 0 group when compared to the day 5 group (2257 vs 940/l, P = 0.030). There was no significant difference in ANC between the two groups for the rest of the period.
Fifty-five of 60 patients enrolled in the study achieved an unsupported platelet count of 20 000/l for 7 consecutive days. Five patients failed to achieve an unsupported platelet count of 20 000/l. All five patients were in the day 0 group (Table 2 , P = 0.020). Two patients (UPNs 26 and 55) died of severe VOD/multiorgan failure on day 44 and 88 before achieving a platelet count over 20 000/l. A patient (UPN 29) died of CNS bleeding on day 29 before platelet engraftment. One patient (UPN 61) died of inter- Table 2 Duration of G-CSF administration, engraftment and transfusion requirements according to early vs late initiation of G-CSF after allogeneic BMT stitial pneumonia on day 61, before platelet engraftment. One patient (UPN 65, severe aplastic anemia) experienced primary graft failure of the erythroid and megakaryocytic series but successfully restored full engraftment after donor peripheral progenitor cells were infused on day 90 and was considered as initial platelet engraftment failure. Median times to unsupported platelet counts of 20 000/l, 50 000/l and 100 000/l in the two groups did not show statistically significant differences ( Table 2 , Figures 1b and  2b) . Median times to the achievement of RBC transfusion independence over a month and to reticulocyte count equal or over 1% did not show statistically significant differences ( Table 2 ). Red blood cell and platelet transfusion requirements within 60 days of BMT in both groups were similar and did not show statistically significant differences ( Table 2) .
Hepatic VOD
There were 20 patients (66.7%) who experienced VOD in the day 0 group in contrast to 12 patients (40.0%) in the day 5 group (Table 3 , P = 0.038). When the data were analyzed in terms of maximum weight gain and maximum serum total bilirubin level during the immediate post-BMT period, median values of maximum weight gain and number of patients gaining over 2% of body weight were similar in both groups ( Table 3 ). The median values of maximum serum total bilirubin levels tended to be higher for the patients in the day 0 group during days 6-10 and days 11-20, but the differences were not statistically significant. The numbers of patients experiencing serum total bilirubin level equal or over 2 mg/dl were also higher for the day 0 group of patients, especially during the day 6-10 period (Table 3) . A cumulative incidence curve of VOD of each group is depicted in Figure 3 .
When we compared the clinical characteristics of VOD occurring in each group of patients, there was no significant difference in terms of clinical severity, day of onset, duration, maximum weight gain, as well as maximum serum total bilirubin level (Table 4) .
GVHD and other complications
Four patients (13.3%) of each group experienced acute GVHD (Table 5 ). Twelve patients (40.0%) of the day 0 group and 10 patients (33.3%) of the day 5 group experienced chronic GVHD. Frequencies of GVHD in both groups were similar. There was no significant difference in the frequencies of infections in both groups of patients (Table 5) . Table 6 shows the changes in natural anticoagulants (protein C, free protein S, and ATIII), as well as vWF and factor VIII. None of the parameters was significantly differ- ent at the baseline or on day 0 of BMT between patients in day 0 and day 5 groups. On day 7, mean plasma level of ATIII in the day 0 group of patients was significantly lower when compared to that of the day 5 group (Table 6 , P = 0.009, Figure 4b ). Mean plasma protein C level fell by day 14 in both groups of patients when compared to baseline (Figure 4a) . Mean plasma vWF level rose by day 7 in both groups of patients when compared to baseline (Figure 4c ). There were no significant differences in protein C, free protein S, vWF, and factor VIII levels between the two groups of patients (Table 6 ).
Changes in coagulation parameters
Survival
The median follow-up time of patients who were alive at the time of the analysis was 558 days (range, 179-1148 days). Nine and six patients from each group died (Table 5, 596  Table 3 Frequency of VOD, maximum weight gain, and maximum hyperbilirubinemia after allogeneic BMT according to early vs late initiation of G-CSF after allogeneic BMT Student t-test after log conversion. Two patients who developed VOD before day 0 of BMT were assumed to have developed VOD on day 0 for the purpose of plotting of the curves. Figure 5 ). Overall survivals in both groups did not show a statistically significant difference, although there were more deaths occurring early after BMT in the day 0 group of patients. The median times of occurrence of death were day 95 (range, 29-831) in the day 0 group and day 234 (range, 107-531) in the day 5 group. When we compared 100 day survivals of the two groups, the day 0 group showed significantly worse survival when compared to the day 5 group (25/30 vs. 30/30 surviving respectively, P = 0.019 by logrank test). Two patients in the day 0 group died of VOD/multiorgan failure on days 44 and 88, respectively. None of the patients in the day 5 group died of VOD or multiorgan failure. Other causes of death are listed in Table 5 . 
Clinical outcomes
Discussion
Although hematopoietic colony-stimulating factors are widely used in the setting of progenitor cell transplantation, optimum timing of initiation of hematopoietic colony-stimulating factors remains to be defined. In our prospective study, we compared the effect of randomly assigned treatment of G-CSF in allogeneic BMT by either starting G-CSF on the day of bone marrow infusion (day 0 group) or on the 6th day after bone marrow infusion (day 5 group). The dose of G-CSF was 450 g given intravenously over 3 h daily and continued until peripheral blood ANC of the patients reached 3000/l. Our study showed that earlier 597 Table 5 Other clinical outcomes according to early vs late initiation of G-CSF after allogeneic BMT 
Table 6
Plasma levels (mean Ϯ standard deviation) of coagulation parameters at five different times according to early vs late initiation of G-CSF after allogeneic BMT initiation of G-CSF after allogeneic BMT did not facilitate engraftment of the donor marrow. We also found that earlier initiation of G-CSF was associated with significantly more cases of VOD along with a higher incidence of hyperbilirubinemia (Table 3) . Such clinical effects were further substantiated by the laboratory evidence of change in one of the hemostatic parameters, ATIII, which fell significantly by day 7 of BMT in patients starting G-CSF early (Table 6 ). VOD is a major early complication after BMT. [17] [18] [19] [20] [21] [22] The primary cause of VOD after BMT was felt to be a toxic effect of cytoreductive chemotherapy or chemoradiotherapy which results in the damage to hepatic venular and sinusoidal endothelium and subsequently to the hepatocytes in zone 3 of the liver acinus. This damage triggers the coagulation cascade, induces the thrombosis of the hepatic venules and eventually leads to fibrous obliteration of the affected venules. In addition to direct chemical injury to vascular endothelium and coagulation system activation, there has been evidence that cytokines such as tumor necrosis factor-␣ (TNF-␣) and interleukin-1␤ (IL-1␤) are involved in the pathogenesis of VOD. [23] [24] [25] It is well known that G-CSF modulates release of proinflammatory cytokines such as TNF-␣, interleukin-6 (IL-6), and interleukin-8 (IL-8) from the macrophages and other reticuloendothelial cells. In a study of Pajkrt et al, 7 the modulation of cytokine release by G-CSF was time-dependent. G-CSF enhanced the release of proinflammatory cytokines when it was administered 2 h before a challenge with endotoxin in healthy volunteers. On the other hand, G-CSF reduced the cytokine release when administered 24 h before endotoxin challenge. Our study showed that administration of G-CSF early in the course of allogeneic BMT may increase the incidence of VOD after allogeneic BMT. It is likely that the administration of G-CSF early after the completion of preparative chemotherapy enhanced damage to hepatic venular and sinusoidal endothelium. Although it is not certain whether the effect was due to a direct effect of G-CSF on the endothelium or mediated through the proinflammatory cytokines such as TNF-␣, it is likely that proinflammatory cytokines played an important role. Activated neutrophils with their degranulation products, whose release was enhanced by the presence of a higher level of G-CSF in the system might have contributed to the hepatic endothelial damage as well. It is interesting to note that the mean ANC on day 3 of BMT was significantly higher in the day 0 G-CSF group of patients when compared to the day 5 group in our study (Figure 2a ). These are likely to be activated neutrophils released from the residual bone marrow of patients by G-CSF. Our study suggests that the increased TNF-␣ level observed in the study of Holler et al 23 before the development of VOD after BMT is a causative or at least a contributing factor for the development of VOD and not an epiphenomenon. It is also in agreement with a theory of a common, immunologic pathogenesis of VOD, systemic inflammatory response syndrome and multiple organ dysfunction syndrome, where proinflammatory cytokines were felt to play a central role. 26, 27 A decreased serum level of protein C and ATIII has been observed during the course of VOD. 19, 28, 29 The degree of fall of serum ATIII showed positive correlation with severity of VOD. 19, 26 In our study, the serum level of ATIII was significantly lower in the day 0 group of the patients by day 7 of BMT, which also suggested the pathogeneic role of G-CSF in VOD.
Initiation of rhG-CSF
The association between the use of hematopoietic growth factors such as G-CSF and GM-CSF and the higher incidence of VOD after BMT has not been reported in the past. The reported incidence of VOD in different series of BMT patients varies widely and ranges from less than 10% to over 50% depending on the criteria used for the diagnosis of VOD and how rigorously the patients were monitored. [17] [18] [19] [20] [21] [22] Milder forms of VOD could have been easily overlooked in trials investigating the role of hematopoietic growth factors in a setting of BMT. A significant fall in hemoglobin level and platelet count as well as a significant rise of plasma urea and bilirubin level were observed in GM-CSFtreated patients in a placebo controlled study of Powles et al, 9 where GM-CSF was started on the day of marrow infusion. The diagnostic criteria of VOD and the incidence of VOD were not recorded in their study.
All patients with malignant disorders including myelodysplastic sydrome received the BuCy regimen as conditioning for BMT in our study, where busulfan was given orally. It is well known that there is wide pharmacokinetic variation among patients when busulfan is given orally. 30 Since we did not measure blood busulfan levels in our patients, we can not rule out the possibility that differences in busulfan pharmacokinetics caused a different incidence of VOD in our study.
Although, overall survivals of the patients in both treatment groups were similar, the higher 100 day mortality rate in the day 0 group of patients may be related to earlier administration of G-CSF. Of five deaths occurring within 100 days of BMT in day 0 group of patients, two died of VOD. None of the patients in the day 5 group died of VOD. A significantly lower proportion of patients in the day 0 group achieved platelet and RBC transfusion independence ( Table 2) .
Lack of effect on neutrophil engraftment time between the two groups of patients suggests that G-CSF does not play a significant role in the early homing process of hematopoietic progenitor cells.
In conclusion, our study showed that early administration of G-CSF does not facilitate marrow engraftment when compared to delayed administration of G-CSF after allogeneic BMT. In addition, early administration of G-CSF was associated with a higher frequency of VOD and a significant fall in plasma ATIII level. Further studies are warranted to investigate the role of G-CSF in the pathogenesis of VOD especially when it is administered early after completion of the preparative regimen in a setting of BMT.
